Precigen (PGEN) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Precigen (PGEN) do?
Precigen Inc (PGEN) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Develops clinical-stage gene and cellular therapies using non-viral DNA vectors for cancer and infectious diseases. Develops targeted cell and gene therapies using non-viral genetic platforms to treat rare diseases and cancers. It is worth $1.49B on the market and sold $157.01M over the last year.
- Market cap
- $1.49B
- P/E ratio
- 93.1×
- Annual sales
- $157.01M
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 17, 2026
PGEN’s flags, in plain English
Each flag is a number from Precigen’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 17, 2026.
Stupid Cash
Can pay this year's bills 5.6 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Wide Gross Margin
Gross margin of 90.6% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Earnings Jumping
Profits up 117.7% this year. Profit per share is growing fast this year. One year does not make a trend, so check whether sales grew too.
Priced for Perfection
Priced at 93.1 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.
2 more green flags and 2 more risk notes open with the free trial. Try it free for 7 days.
Questions about PGEN
How big is Precigen?
Precigen’s market cap is $1.49B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $157.01M: what customers paid the company over the last year, before any costs.
What is PGEN’s P/E ratio?
PGEN’s P/E ratio is 93.1×. Investors pay about 93.1 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with PGEN?
The company operates without commercial product sales and relies on equity financings to cover operational cash burn. That is one risk on Precigen’s card. Its first risk flag is Priced for Perfection, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Precigen’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. PGEN’s filings on SEC.gov. The Margin Monkey is research, not advice.
